Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers

Al-saraireh, Yousef M.; Alshammari, Fatemah O F O; Youssef, Ahmed M M; Al-Sarayreh, Sameeh; Almuhaisen, Ghadeer H; Alnawaiseh, Nedal; Shuneigat, Jehad M Al; Alrawashdeh, Hamzeh Mohammad

doi:10.1038/s41598-021-85188-4

Cited by 27 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these studies, CYP4Z1 was expressed at much higher levels in cancers of the breast, ovary, and prostate than in their corresponding normal tissues [ 8 , 10 , 11 ]. Moreover, we recently identified a similar fashion of CYP4Z1 differential expression in bladder [ 14 ] and colon cancers (data not published).…”

Section: Discussionmentioning

confidence: 85%

“…Several studies reported differential expression of CYP4Z1 in cancers of the breast, ovary, and prostate [ 8 , 11 , 12 , 13 ]. Recently, we characterised CYP4Z1 expression in bladder [ 14 ]. Importantly, its expression is associated with poor patient prognosis and has been suggested as a biomarker for cancers of the ovary and prostate [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: cervical cancer is one of the most common malignancies in women worldwide and its management remains challenging and complex. As Cytochrome4Z1 (CYP4Z1) is overexpressed in many tumours, its expression in cervical cancer is unknown. Therefore, the present study aimed to evaluate CYP4Z1 expression in cervical cancers. Methods: CYP4Z1 expression was immunohistochemically assessed in 100 cases of cervical cancers along with ten normal cervix tissues, and the enzyme’s relationship to several clinicopathological features and survival was explored. Results: CYP4Z1 was strongly expressed in 55% of cervical cancer patients. Normal cervix samples were negative for CYP4Z1 expression. Importantly, this expression was significantly found in patients with the late stage of the disease, lymph node metastasis, and high tumour invasion (p < 0.05). Interestingly, CYP4Z1 expression was significantly correlated with shorter survival times of cervical cancer patients. Univariate analysis showed that CYP4Z1 expression, tumour stage, lymph node metastasis, and tumour invasion were significantly correlated with patient survival (p < 0.05). The multivariate analysis revealed that only CYP4Z1 expression and tumour stage were significantly correlated with patient survival (p < 0.05). Conclusions: CYP4Z1 expression is associated with cervical cancer patients’ survival and may serve as an independent predictor of poor prognosis in cervical cancer patients.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 It is of importance that studies have reported uniquely strong expression of CYP4Z1 in several cancers. [4][5][6][7][8][9] Its expression has been linked with poor tumor grade and higher patient mortality, and it has been proposed as a biomarker for ovarian, prostate and cervical cancers. 5,6,10,11 Interestingly, an abnormal translocation of CYP4Z1 expression on the surface of breast cancer cells has been reported, but no expression was observed in healthy control mammary cells.…”

Section: Introductionmentioning

confidence: 99%

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers

Al-saraireh¹,

Alshammari²,

Youssef³

et al. 2021

BCTT

Self Cite

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is characterized by high mortality rate, and its clinical management is difficult and complex. Therefore, there is a need for extensive efforts aimed at accelerating the discovery of novel therapies for TNBC. CYP4Z1 has been implicated in the development of breast cancer. The current study aimed at characterizing the expression of CYP4Z1 on TNBC. Materials and Methods: Using immunohistochemistry, CYP4Z1 expression was evaluated on 122 TNBC samples, four samples of breast cancers expressing ER, PR, and HER-2, and four samples of normal breast tissues. The association between the enzyme and various histopathological features and survival of patients were determined. Results: CYP4Z1 was strongly expressed in 83.3% of various histopathological subtypes of TNBC, when compared to negative expression in normal breast tissues. Interestingly, there were marked variations in CYP4Z1 expression with respect to histopathology subtype, histological grade, histological stage and tumor diameter. There was a high incidence of CYP4Z1 expression in patients with advanced grades, late stages and larger tumor sizes. Importantly, CYP4Z1 expression was correlated with the survival of TNBC patients, but it was an independent determinant of the poor prognosis of TNBC (p< 0.05). Conclusion: CYP4ZI may be a potential biomarker or target for evolving new CYP4Z1targeted treatments.

show abstract

“…Several studies have indicated selective CYP1B1 expression in many cancers [ 11 , 12 , 14 , 16 , 19 - 21 ]. However, neither of these studies have investigated CYP1B1 expression in cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Importantly, CYP1B1 has recently been proposed as a universal tumor antigen owing to its selective overexpression in tumors compared to negative or undetectable levels of protein expression in the corresponding normal tissues [11]. A high frequency of CYP1B1 expression has been reported in cancers of the brain, breast, prostate, colon, bladder, muscle (rhabdomyosarcoma), ovary, and lungs (non-small cell lung cancer) [11][12][13][14][15][16][17][18][19][20][21][22]. Moreover, metastatic tumors show an elevated level of CYP1B1 expression [14].…”

Section: Introductionmentioning

confidence: 99%

Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study

et al. 2021

View full text Add to dashboard Cite

Background Current standard treatments for patients with recurrent cervical cancer are not very effective and are associated with severe toxicity. Recently, the rational approach for the discovery of new therapies for cervical cancer is based on the alterations in the molecular biology of cancer cells. One of the emerging molecular changes in cancer cells is the aberrant expression of cytochrome P450 1B1 (CYP1B1). This unique enzyme has been reported to be selectively overexpressed in several cancers. Objective The aim of this study was to examine CYP1B1 expression in cervical cancers and to assess the enzyme’s relationship with several clinicopathological features. Methods Immunohistochemistry was performed to examine CYP1B1 expression in 100 patient samples with cervical cancer and 10 patient samples with normal healthy cervical tissues. Results CYP1B1 was expressed in the majority of the cervical cancer samples (91/100, 91.0%) but not in normal healthy cervical samples. The difference in the expression of CYP1B1 between healthy and tumorous cervical tissues was significant (P=.01). Moreover, the frequency of CYP1B1 expression was found to be significantly higher in patients with advanced grades of the disease (P=.03) and in patients having metastasis to the lymph nodes (P=.01). Surprisingly, there was a significantly higher expression of CYP1B1 in patients with a high prevalence of human papilloma virus 16/18 (P=.04). Conclusions The differential profile of CYP1B1 expression between cervical cancer tissues and normal cervical tissues suggests that CYP1B1 may be used as a target for future therapeutic exploitations.

show abstract

Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers

Cited by 27 publications

References 26 publications

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers

Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study

Contact Info

Product

Resources

About